Gilead­'s her­pes deal; FDA ap­provals for Boehringer, Roche
Plus, news about Bio­Marin and Cas­sa­va.
Gilead opts in­to As­sem­bly Bio’s gen­i­tal her­pes pro­grams:
As a re­sult, Gilead will pay As­sem­bly 5 mil­lion based …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Al­tim­mune ad­vances in MASH; New Chi­na obe­si­ty biotech; Ipsen Phase 2 fail
Sub­cu­ta­neous Ry­bre­vant; Kalaris shares nAMD da­ta; Pyx­is dis­ap­points
Vir li­cens­ing deal; Cy­to­ki­net­ics wins Chi­na nod; Vista­gen's so­cial anx­i­ety fail
Client Engagement Mgr - Life Sciences Strategy & Intelligence
Up­dat­ed: Pfiz­er dis­clos­es pa­tient death in Hym­pa­vzi he­mo­phil­ia tri­al
Drug­mak­ers with White House MFN deals claim ex­emp­tion from pro­posed Medicare pric­ing tests
No­vo Nordisk eyes a strong launch with FDA ap­proval of obe­si­ty pill
Neu­ro­crine’s In­grez­za flunks piv­otal study in dys­k­i­net­ic cere­bral pal­sy
The End­points win­ners and losers list: Who was up and who was down in 2025
Up­dat­ed: Bris­tol My­ers, J&J bring IRA fight to Supreme Court as 'regime of forced sales' is poised to take ef­fect